Monte Rosa Therapeutics, Inc. (GLUE) reported Q2 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts GLUE Hot Sheet
Join SI Premium – FREE
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q2 Revenue for the quarter came in at $8.97 million versus the consensus estimate of $12.91 million.
For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
